Janssen, a subsidiary of Johnson & Johnson, has submitted its COVID-19 vaccine candidate to Health Canada for approval, making it the fourth candidate in late stage trials to do so. The vaccine is administered as one dose, unlike several others in late stage trials that require two doses. Canada has secured a commitment of up to 38 million doses of Janssen’s candidate, pending it receiving independent regulatory approval from Health Canada. Overall, Canada has secured agreements from 7 manufacturers for up to 429 million doses, the most per capita of any country in the world. Health Canada is currently reviewing candidates on a ‘rolling review process’ from three other manufacturers: Pfizer/BioNTech, Moderna and AstraZeneca.